Cyclerion Therapeutics (CYCN) Insider Trading & Ownership $3.19 +0.24 (+8.14%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Cyclerion Therapeutics (NASDAQ:CYCN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage36.10%Number OfInsiders Buying(Last 3 Years)0Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$27.20 Get CYCN Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclerion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYCN Insider Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Cyclerion Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/9/2023Terrance McguireDirectorSell8$3.40$27.20 (Data available from 1/1/2013 forward) CYCN Insider Trading Activity - Frequently Asked Questions Who is on Cyclerion Therapeutics's Insider Roster? The list of insiders at Cyclerion Therapeutics includes Terrance Mcguire. Learn more on insiders at CYCN. What percentage of Cyclerion Therapeutics stock is owned by insiders? 36.10% of Cyclerion Therapeutics stock is owned by insiders. Learn more on CYCN's insider holdings. Which Cyclerion Therapeutics insiders have been selling company stock? The following insider sold CYCN shares in the last 24 months: Terrance Mcguire ($27.20). How much insider selling is happening at Cyclerion Therapeutics? Insiders have sold a total of 8 Cyclerion Therapeutics shares in the last 24 months for a total of $27.20 sold. Cyclerion Therapeutics Key ExecutivesDr. Regina Graul Ph.D.PresidentMs. Rhonda M. Chicko (Age 58)Chief Financial Officer Dr. Todd Milne Ph.D.Senior Vice President of External InnovationMs. Jessica RennekampAssociate Director of Corporate Communications More Insider Trading Tools from MarketBeat Related Companies VYNE Therapeutics Insider Ownership OncoCyte Insider Ownership Elevation Oncology Insider Ownership CalciMedica Insider Ownership Lumos Pharma Insider Ownership Lantern Pharma Insider Ownership Marker Therapeutics Insider Ownership Tempest Therapeutics Insider Ownership OKYO Pharma Insider Ownership Outlook Therapeutics Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:CYCN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
